Roman et al. found that replication stress is greatly elevated in PBRM1-defective cancers cells, and thereby, they treated PARP and ATR inhibitors via a PBRM1-defective ccRCC model. The gene discussed is PARP1; the disease is nonpapillary renal cell carcinoma.